CD40 Ligand (CD154) Triggers a Short-Term CD4+ T Cell Activation Response That Results in Secretion of Immunomodulatory Cytokines and Apoptosis

By Patrick J. Blair,* James L. Riley,† David M. Harlan,* Ryo A be,§ Douglas K. Tadaki,* Steven C. Hoffmann,* Leonard W hite,* Tara Francomano,* Stephen J. Perfetto,‖ Allan D. Kirk,* and Carl H. June†

From the *National Institute of Diabetes and Digestive and Kidney Diseases-Navy Transplantation and Autoimmunity Branch, Naval Medical Research Center, Bethesda, Maryland 20889-5607; the †University of Pennsylvania, Philadelphia, Pennsylvania 19104; the §Research Institute for Biological Sciences, Science University of Tokyo, Chiba 278-0022, Japan; and the ‖Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland 20889

Abstract

Signals generated through CD28–B7 and CD40 ligand (CD40L)–CD40 interactions have been shown to be crucial for the induction of long-term allograft survivability. We have recently demonstrated that humanized anti-CD40L (hu5C8) prevents rejection of mismatched renal allografts in primates. To investigate potential mechanisms of CD40L–induced allograft acceptance, we coimmobilized hu5C8 with suboptimal amounts of anti-CD3 to stimulate CD4+ T cells. We now report that anti-CD3/CD40L costimulation results in CD28-independent activation and subsequent deletion of resting T cells. Coligation of CD3 and CD40L increased expression of CD69, CD25, and CD54 on CD4+ T cells. We also found that costimulation with anti-CD3/CD40L resulted in enhanced production of interleukin (IL)-10, interferon γ, and tumor necrosis factor α but not IL-2 or IL-6. Interestingly, after several days, anti-CD3/CD40L–mediated activation was followed by apoptosis in a significant population of cells. Consistent with that observation, anti-CD3/CD40L did not enhance the antiapoptotic proteins Bcl-2 and Bcl-xL. Further, the addition of CD28 at 24 h failed to rescue those cells induced to die after costimulation with anti-CD3/CD40L. Together, these data suggest that the graft-sparing effect of hu5C8 in vivo may result in part from early and direct effects on CD4+ T cells, including a vigorous induction of immunomodulatory cytokines and/or apoptosis of allograft-specific T cells.

Key words: costimulatory molecules • T lymphocytes • transplantation • cytokines • apoptosis

Introduction

Binding of CD40 with its counterreceptor, CD40 ligand (CD40L), acts on APCs and T cells in a bidirectional fashion, mediating both humoral and cellular immune responses. In B cells, cross-linking CD40 drives differentiation, proliferation, and isotype switching while preventing B cell apoptosis (1). In T cells, CD40L expression is rapidly but transiently induced after CD3 stimulation (2–4). Much evidence suggests that CD40L is an important regulator of T cell responses. In CD40L-deficient mice, it has been demonstrated that antigen-specific T cell responses were impaired and that therefore the expression of CD40L on T cells was required for the in vivo priming of CD4+ cells (5, 6). Enhancement of T cell responses by CD40L results partially from upregulation of CD80 and CD86 on the APCs (7, 8). CD40L has been shown to induce proliferation and cytokine production in small resting human T cells stimulated with soluble anti-CD3 and CD40-transfected mouse P815 cells (9, 10) and to directly provide signals to CD40L+ Jurkat T cells, which results in neutral sphingomyelinase, c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein (MAP) kinase induction (11, 12).

It is becoming clear that peripheral tolerance to allografts is dependent on the interplay of several costimulatory mol-
cles that work cooperatively to regulate effector functions (13, 14). Acceptance of alloantigens can be induced in adult animals by injection of anti-CD40L antibodies or CD40-deficient B cells (15). Recent reports have shown that antibodies to CD40L in combination with CTLA-4–Ig (CTLA4-Ig) or donor-specific T cells could induce prolonged rejection-free survival of islet, heart, and skin allografts in mice (16–18). Anti-CD40L treatment has also been shown to preserve kidney function in mice with established nephritis (19). We have effectively used a strategy to block costimulatory signals to prevent rejection of primate renal allografts using CTLA4-Ig and the anti-CD40L mAb hu5C8. Whereas costimulation blockade treatment has also been shown to prevent acute rejection and increased kidney allograft survival in nonhuman primates. We also demonstrated that additional immunosuppressants abrogated the effects mediated by hu5C8 (21).

Here, we test the functional effects of the anti-CD40L mAb hu5C8 on purified human CD4+ T cells when coimmobilized with anti-CD3. We compared these findings with results generated in cultures of CD4+ T cells stimulated with anti-CD3 and CD32–CD40– transfectants. Our data demonstrate that CD40L can costimulate CD4+ T cells in the absence of CD28, causing transient thymidine incorporation and activation. CD40L-mediated costimulation was characterized by an increase in T cell activation and adhesion antigens and enhanced production of IFN-γ, TNF-α, and IL-10. However, in anti-CD3/CD40L–stimulated cultures, apoptosis occurred within 3 d in many cells. The paradox of first allowing and then failing to sustain T cell proliferation may suggest a critical role for CD40L in driving short-term T cell effector responses that do not lead to the development of memory.

Materials and Methods

Cells and Antibodies. Freshly isolated PBLs were separated by Percoll (Amersham Pharmacia Biotech) gradient centrifugation from leukopacks obtained by apheresis from healthy donors. CD4+ T cells were purified by negative selection. Hu5C8, an anti-CD40L mAb, was a gift from Dr. Linda Burkly (Biogen, Inc., Cambridge, MA). Anti-CD3 huOKT3 (human IgG1; Ortho Biotech) was a gift of Dr. Jeffrey Bluestone (University of Chicago, Chicago, IL); anti-CD28 9.3 (mouse IgG2a), anti-monomorphic HLA class I mAb W6/32 (mouse IgG2a; American Type Culture Collection), anti-class II mAb 2B6 (mouse IgG1; American Type Culture Collection), and anti-glycophorin A 10FT M C (IgG1; American Type Culture Collection) served as binding and nonbinding controls. Humanized anti-CD80 (1F1, IgG1) and anti-CD86 (3D1, IgG2a) were gifts from Dr. Gary Gray (Genetics Institute, Cambridge, MA). The following anti-bodies were used to immunophenotype T cells: anti-CD4 (clone SK3, IgG1; Becton Dickinson), anti-CD69–PE (clone L78, IgG1; Becton Dickinson), anti-CD25–PE (clone 2A3, IgG1; Becton Dickinson), and anti-CD54 (IgG2a; Immunotech).

Bead Preparation. Anti-CD3 and control or anti-CD40L mAbs were covalently attached to 0.5-μm polyurethane-coated tosyl-activated Dynabeads® (Dynal) according to the manufacturer’s instructions. The bead to cell ratio used in cultures was 3:1. Beads were prepared with a constant amount of anti-CD3 antibody representing 12.5% of bound protein, and with control, anti-CD28, or anti-CD40L mAb to make up the remaining 87.5%.

CD 40+ Transfectants. A full-length cDNA for human (h)CD40 was generated from Raji RNA using primers flanked by KpnI and NcoI sites. This cDNA was cloned into pcDNA 3.1 (Invitrogen), digested with Scal and electroporated into CD32–L cells (a gift of G. Delespesse, University of Montreal, Montreal, Canada) using standard procedures to create CD32–CD40+ L cells. Stable transfectants were generated by staining CD32–Fc–treated cells with an mAb against CD40 (Becton Dickinson) and then performing multiple sterile sorts using an EPICS® ELITE ESP cell sortor (Coulter). CD86–transfected CD32–L cells were a gift of G. Delespesse.

T Cell Function Assay. CD4+ T cells were plated in 96-well flat-bottomed microtiter plates at a density of 106 cells/ml in a total volume of 200 μl RPMI (GIBCO BRL). Proliferation was measured after a pulse with 1 μCi of [3H]thymidine. Cytokine concentrations in cell-free supernatants were assayed by ELISA (R&D Systems). Apoptosis was analyzed using a modified terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL)-based procedure (22).

PCR-based Liquid Hybridization Assay. Steady state cytokine mRNA levels were assayed by semiquantitative reverse transcriptase (RT)-PCR-based liquid hybridization using the following primers and probes as described previously (23). RT–generated PCR products were diluted as indicated in the figure legends. To ensure that the PCR reactions were performed in the linear range of the assay, a twofold dilution of the RT product was amplified at 95°C for 0.5 min, 55°C for 0.5 min, and 72°C for 1.5 min for 25 cycles with the primers listed below. Liquid hybridization of the PCR products was conducted as reported previously. In brief, samples were loaded into 10% acrylamide gels, run at 140 V for 75 min, and then exposed to a PhosphorImager® screen (Molecular Probes). Assays were validated by determining whether twofold differences in signal strength could be detected. Primers were as follows: for IL-2 (sense) 5′-CAA CTC CTT GCT TCT GCG ATT GC-3′, (antisense) 5′-TTC TGT GGC CTT CTT GGG-3′, (probe) 5′-ACA AGA ATC CCA AAC TCA CCA GG-3′; for IL-6 (sense) 5′-AGG GGG CAG GTG AAG GTC-3′, (antisense) 5′-CCT CAA ACT CAA AAG GCA-3′, (probe) 5′-GAG AAA GGA GAC ATG TAA C-3′; for IFN-γ (sense) 5′-ACA GAG TTG CCT GGT CGT CT-3′, (antisense) 5′-ATG AAG CAT CTC GTG AAC AA-3′, (probe) 5′-ATG AAG CAT CTC GTG AAC AA-3′; for TNF-α (sense) 5′-TGC AGG TCA TCT TGT TTC TGG-3′, (antisense) 5′-AGG GGG CAG GTG AAG GTC-3′, (probe) 5′-AGG GGG CAG GTG AAG GTC-3′.
CD25, CD54, and CD40L–induced responses at 24 h was surprising; there-
sumably to amplify and sustain signals through the TCR.

Results and Discussion

Anti-CD3/CD40L Stimulation Provides a Costimulatory Signal to Resting Human CD4+ T Cells. CD40L is rapidly
expressed at levels comparable to those seen in anti-CD3/CD40L–stimulated cells. The intensity of anti-CD3/CD40L–induced responses at 24 h was surprising; therefore, we determined the kinetics of CD25, CD54, and CD69 expression (Table I). Cells were stimulated optimally with anti-CD3/CD28-coated, with anti-CD3/CD40L-coated beads, or with control beads that either bound (anti-MHC I) or did not bind (glycophorin) T cells. Inter-
esting, our results showed that CD3/CD40L oligation had the capacity to induce an early activation response in T cells, resulting in significant increases in the expression of these markers. However, the duration of anti-CD3/CD40L responses decreased markedly by 48 h. These results are comparable to the anti-CD3/CD40L–mediated thymidine incorporation we had previously measured (Fig. 1) and suggest that coligation of CD3 and CD40L on T cells alone does not lead to sustained activation.

Anti-CD28-independent Effects after Anti-CD3/CD40L Costimulation. CD28 is necessary for sustained antigen-depen-
dent T cell proliferation (27). Anti-CD28 Fab fragments

Figure 1. Anti-CD3/CD40L stimulation provides a costimulatory signal for purified human CD4+ T cells. (A) Purified CD4+ T cells were cultured with beads coated with anti-CD3 antibody in combination with anti-CD40L, anti-CD28, or control MHC class I, MHC class II, or glycophorin (Gly.) antibodies at a 3:1 cell to bead ratio for 54 h. Cells were also cultured with anti-CD3/CD28-coated beads in combination with either MHC class I or CD40L mAbs. Cultures were pulsed and harvested after an additional 18 h. Data represent the mean ± SEM from three separate as-
says. (B) Expression of activation and adhesion molecules in purified CD4+ T cells after 24-h stimulation with either anti-CD3/MHC class I (control), anti-CD3/CD40L, or anti-CD3/CD28. Representative fluorescence histograms of isotype control reagents (thin lines) and either CD69, CD25, or intracellular adhesion molecule (ICAM) (thick lines) are shown. Histograms were first gated on live CD4-FITC–stained cells.
Table I. Immunophenotyping Kinetics on Stimulated CD4<sup>+</sup> T Cells

| Stimulation   | Time | % CD25 ±SEM | % CD54 ±SEM | % CD69 ±SEM |
|---------------|------|-------------|-------------|-------------|
| CD3/glycophorin | 12   | 4.0 ± 0.4   | 0.7 ± 0.1   | 20.8 ± 5.3  |
|               | 24   | 6.7 ± 0.4   | 0.9 ± 0.1   | 23.9 ± 6.1  |
|               | 48   | 7.1 ± 0.2   | 0.8 ± 0.4   | 25.4 ± 6.7  |
|               | 72   | 4.8 ± 0.2   | 1.3 ± 0.5   | 23.3 ± 5.5  |
|               | 96   | 3.9 ± 0.5   | 0.9 ± 0.2   | 17.7 ± 5.6  |
| CD3/CD40L     | 12   | 2.8 ± 0.1   | 1.2 ± 0.1   | 12.6 ± 5.3  |
|               | 24   | 3.7 ± 0.4   | 2.2 ± 0.4   | 12.3 ± 4.0  |
|               | 48   | 7.6 ± 0.8   | 1.6 ± 0.3   | 14.5 ± 2.3  |
|               | 72   | 6.8 ± 1.0   | 1.6 ± 0.4   | 13.4 ± 6.2  |
|               | 96   | 4.4 ± 1.2   | 1.2 ± 0.2   | 12.9 ± 5.2  |
| CD3/MHC I     | 12   | 14.9 ± 3.5  | 3.7 ± 2.0   | 57.3 ± 5.0  |
|               | 24   | 48.3 ± 7.1  | 21.5 ± 4.0  | 68.4 ± 7.1  |
|               | 48   | 31.9 ± 4.3  | 11.0 ± 2.3  | 56.0 ± 3.8  |
|               | 72   | 24.4 ± 4.5  | 7.1 ± 1.2   | 39.2 ± 7.5  |
|               | 96   | 17.2 ± 3.2  | 4.1 ± 0.8   | 29.8 ± 1.3  |
| CD3/CD28      | 12   | 69.1 ± 1.0  | 14.4 ± 0.5  | 78.1 ± 2.6  |
|               | 24   | 83.3 ± 2.5  | 31.1 ± 4.2  | 84.8 ± 1.5  |
|               | 48   | 92.0 ± 0.7  | 45.3 ± 5.4  | 94.5 ± 0.5  |
|               | 72   | 95.6 ± 0.2  | 62.0 ± 5.0  | 91.4 ± 1.0  |
|               | 96   | 97.3 ± 1.2  | 44.5 ± 3.5  | 86.2 ± 1.3  |

Cells were stained as described in Materials and Methods and labeled with the indicated mAbs. Percent frequencies are shown for 5 × 10<sup>4</sup> lymphocytes first gated as CD4-PE<sup>+</sup>. SEM shown from three to four separate donors.

and antibodies to CD80 and CD86 block T cell proliferation induced by plant lectins or anti-CD3 (28). To test whether the CD40L receptor–induced costimulatory effects were CD28 dependent, we treated anti-CD3/CD40L-stimulated cultures with agents that prevent CD28-mediated responses. As shown in Fig. 2, CD40L–induced T cell activation is largely CD28 and CD80/CD86 independent, as judged by the relative inability of these reagents to block T cell thymidine incorporation. In separate reagent control experiments, we found that the CD28 Fab fragments and CD80/CD86 antibodies had retained full inhibitory activity (data not shown). Costimulation through CD28 drives cyclosporin A (CSA)-independent T cell proliferation, cytotoxic activity, and the increased production of cytokines including IL-2, IFN-γ, and TNF-α through both de novo synthesis and mRNA stabilization (29). CSA, which inhibits calcineurin activation through the TCR (30), has been shown to block induction of T cell apoptosis (31). In Fig. 2, we found that, unlike CD28 (32), CD40L–induced thymidine incorporation was sensitive to CSA treatment in a dose-dependent fashion. Subsequently, we determined that CD40L expression decreased on human CD4<sup>+</sup> T cells as CSA concentrations increased (data not shown). This observation is consistent with previous studies (33) and suggests that concurrent treatment of transplant recipients with CSA and hu5C8 could reduce the effectiveness of events mediated through CD40L.

Finally, our results demonstrate that the addition of exogenous IL-2 further augmented the thymidine incorporation induced by anti-CD3/CD40L–coated beads (Fig. 2). This is also consistent with the notion that anti-CD3/CD40L- and anti-CD3/CD28–stimulated T cell activation are distinct, as the addition of exogenous IL-2 did not further stimulate anti-CD3/CD28–stimulated T cells (data not shown).

Measurement of Cytokine mRNA and Protein Levels in Anti-CD3/CD40L–stimulated CD4<sup>+</sup> T Cells. Experiments in CD40L-deficient and CD40-deficient mice have shown that CD40–CD40L interactions play an important role in regulating cytokine responses (34, 35). Ligation of CD40 on T cells is crucial for the T cell contact–dependent signaling to induce nitric oxide and cytokine production (36), indicating that CD40L may be involved in inhibiting T cell activation responses. While most available information indicates that CD40L regulates cytokine secretion indirectly through its effects on APCs, the ability of CD40L to induce CD4<sup>+</sup> T cell activation suggested that CD40L might have direct effects on T cell cytokine secretion. To test this possibility, we assayed cytokine levels in cells stimulated with anti-CD3/CD40L–coated beads compared with anti-CD3/CD28–coated beads or with beads coated with anti-CD3/CD40L.
CD3/MHC class I mAbs (Fig. 3). Using first a semiquantitative RT-PCR-based assay, we measured IL-2, IL-6, IL-10, and IFN-γ mRNA transcripts in cells activated for 24 h (Fig. 3 A). We found high levels of IL-10 and IFN-γ transcripts induced in CD41 T cell cultures stimulated with anti-CD3/CD40L-coated beads and low or undetectable levels of IL-2 and IL-6 transcripts. In contrast, in cells stimulated with anti-CD3/CD28-coated beads, we identified high amounts of IL-2, IFN-γ, IL-6, and IL-10 transcripts. When cultures were examined earlier (after 4–8 h of culture), high levels of TNF-α transcripts were seen in both CD3/CD40L- and CD3/CD28-stimulated cultures while we continued to observe that IL-2 transcripts were restricted to the CD3/CD28-stimulated cultures (data not shown).

We also examined the accumulation of cytokines in the supernatants of CD41 cells by ELISA (Fig. 3 B). These results confirmed the large (>100-fold) difference in IL-2 secretion between anti-CD3/CD28- and anti-CD3/CD40L-stimulated cultures. In marked contrast, the anti-CD3/CD40L-stimulated cultures had high and sustained levels of IL-10 that were equivalent to those found in CD3/CD28-stimulated cultures. The decrease in IL-10 was specific to anti-CD3/CD40L cells, as cultures stimulated with the control CD3/MHC class I beads did not accumulate IL-10. Levels of TNF-α and IFN-γ were also elevated in the supernatants from the CD3/CD28-stimulated cultures, demonstrating that both Th1- and Th2-type cytokines had been secreted.

CD32CD40L transfectants induce CD4+ T cell proliferation and production of immunomodulatory cytokines, but not IL-2. To determine whether the cytokine profiles we found in anti-CD3/CD40L bead-stimulated cells were unique to this model system and/or to the anti-CD40L mAb 5C8, we generated CD40L-transfectants by electroporation of human CD40 into CD32+ mouse L cells (Table II). The CD32 receptor transfected previously in these cells bound soluble anti-CD3 (huOKT3). We found that upon addition of anti-CD3, CD40L-L cells are potent stimulators of purified populations of CD4+ T cells, leading to activation responses similar to those results generated in our studies with anti-CD3/CD154-coated beads. In these experiments, we measured cell proliferation, and IL-2, IL-10, IFN-γ, and TNF-α production. Responses were compared against CD86-transfected CD32+ L cells and CD32+ L cells that bound anti-CD3. As evident in Ta-

Table II. Cytokine Expression at 72 h in Supernatants from Stimulated CD4+ T Cells

| Stimulation* | IL-2 | IL-10 | IFN-γ | TNF-α | Thymidine incorporation |
|--------------|------|-------|-------|-------|------------------------|
| CD40+ L cells | <31.2 | 0 | 10 | <15.2 | 2,597 |
| anti-CD3 | 42 | 163 | 333 | <15.2 | 19,201 |
| CD40+ L cells + anti-CD3 | 63 | 494 | 8,936 | 7,286 | 31,308 |
| B7-2+ L cells + anti-CD3 | 5,418 | 191 | 7,388 | 7,286 | 21,022 |

Supernatants were collected from stimulated cells after 72 h culture, and IL-2, IL-10, IFN-γ, and TNF-α production were measured by ELISA as described in Materials and Methods. Results (in pg/ml) are a representation from two to three separate assays using different donors. *CD4+ T cells were plated in 24-well culture dishes over CD32+ mouse L cells that were either not transfected, or were transfected with human CD40 or CD86. Where noted, anti-CD3 (OKT3) was added at a concentration of 200 ng/ml. Previously, we had optimized anti-CD3-mediated effects in L cells by titrating concentrations.
ble II, we saw significant thymidine incorporation in anti-CD3-treated CD40+ L cells that was comparable to levels seen in CD80 and CD86 transfectedants and almost double the levels in L cells treated with anti-CD3 alone. Of interest, we noted that while anti-CD3-treated CD40+ L cells did not produce IL-2, significant amounts of IL-10 and IFN-γ were made. These results complement what we have documented above using anti-CD3/CD40L-coated microspheres and suggest that stimulation through CD40-CD40L without concurrent ligation through CD28 has a direct effect on CD4+ T cells that results in the upregulation of the immunosuppressive cytokines IL-10, TNF-α, and IFN-γ, but not IL-2.

In both anti-CD3/CD40L-ligated and anti-CD3 CD40+–transfected CD4+ T cells, we noted significant IL-10 production. IL-10 is a potent immunosuppressive cytokine that acts to prevent autoimmune disease onset (insulin-dependent diabetes mellitus) in nonobese diabetic (NOD) mice (37, 38). Others have shown that chronic activation of both human and murine CD4+ T cells in the presence of IL-10 gives rise to CD4+ T cells with low proliferative capacity that produce high levels of IL-10 and low levels of IL-2. These antigen-specific T cells suppress the proliferation of CD4+ T cells in response to antigen (39). We speculate that CD3/CD40L-activated CD4+ T cells may result in the unique cytokine production profile described, and that these cytokines may contribute to the overall immunosuppressive effects of CD40L mAb observed in vivo.

The production of IL-2 by activated T cells is an autocrine signal that leads to T cell proliferation and the development of effector functions, and thus is important in the understanding of costimulator regulators such as CD40L in T cell responses. Interestingly, unlike earlier reports (9, 10), which used the same transfected mouse cell line, we found that in both our bead and CD40-transfected cell models costimulation through anti-CD3/CD40L did not lead to an increase in IL-2. In fact, levels of IL-2 induced by anti-CD3/CD40L stimulation were similar to levels seen in anti-CD3/MHC class I–stimulated cells and dramatically lower than levels seen in anti-CD3/CD28 bead cultures or B7-2–transfected L cells (Fig. 3 B, and Table II). These results clearly demonstrate that although CD25 is upregulated on the surface of anti-CD3/CD40L–stimulated human CD4+ T cells, little or no IL-2 is actually produced after anti-CD3/CD40L ligation. We cannot rule out the possibility that small amounts of IL-2 induced by CD40L costimulation may have been rapidly reincorporated by the cultured cells. Our findings are supported by other studies. Johnson-Leger et al. demonstrated that CD3-primed CD40L+ T cells were incompetent helper cells because they secreted insufficient IL-2 (40). They proposed that CD4+ T cells must first encounter antigen in conjunction with CD28/B7 interactions before CD40L is stabilized on the surface and IL-2 is produced (41). Additionally, Gray and colleagues used CD40L knockout mice to show that CD40L delivers signals to T cells that enhanced the maturation of IFN-γ and played a role in the development of Th2 cells to optimize IL-4 secretion. However, they found that CD40L ligation had no effect on IL-2 production (42).

In many regards, our results are similar to those seen by Cayabyab et al. (9) and Peng et al. (10). For instance, they measured appreciable levels of IL-10 and IFN-γ after culture of T cells with anti-CD3 and CD40+ transfectants. Within the transfected mouse cell system, however, the impact of additional costimulatory pathways cannot be ruled out. For instance, recently an additional and novel homologue of CD80/CD86 was discovered that is induced by TNF-α (43). Further, unlike previous work, we used either purified CD4+ T cells that were stimulated by anti-CD3/CD40L on three-dimensional beads or anti-CD3–treated CD32+CD40+ L cells, both of which allowed close proximity of the coligated signals. Overall, these data strongly suggest that although signals through CD3 and CD40L are sufficient to induce short-term proliferation, they are inadequate to drive IL-2 production and cell cycle progression.

Effects of Anti-CD3/CD40L Costimulation on Apoptosis and Expression of Cell Survival Proteins. Programmed cell death is an important mediator of homeostasis within the immune system. To test whether engagement of CD40L might enhance the probability of apoptosis, we first measured viability kinetics using trypan blue exclusion. Consistent with our hypothesis, cell viability plummeted to <60% by 144 h (Fig. 4 A) after anti-CD3/CD40L stimulation. In comparison, anti-CD3/CD28–stimulated cultures maintained >95% viability. To test whether CD4+ T cells were dying via apoptosis, we analyzed DNA fragmentation using the TUNEL assay (Fig. 4 B). Compared with anti-CD3/MHC class I–treated cultures (<6%) or anti-CD3/CD28–treated cultures (<3%), high levels of apoptosis were evident at 72 h in anti-CD3/CD40L–coligated cultures (18%). To test whether apoptosis was mediated by Fas or in an autocrine fashion by TNF-α secretion, we treated anti-CD3/CD40L–stimulated cultures with neutralizing antibodies to FasL or TNF-α (data not shown). Treatment with these neutralizing antibodies did not appreciatively decrease levels of anti-CD3/CD40L–induced apoptosis, suggesting an independent mechanism of death. As CD28–mediated costimulation is known to stimulate production of the cell survival protein Bcl-xL within T cells (44), we assayed anti-CD3/CD40L–stimulated T cells to see if a failure to induce Bcl-xL might correlate with the apoptosis we had observed. Consistent with the increased apoptosis observed in anti-CD3/CD40L–stimulated T cells, using immunoprecipitation and Western blotting we found a complete lack of Bcl-xL (Fig. 4 C). In contrast, CD4+ T cells exhibited high levels of Bcl-xL after stimulation with anti-CD3/CD28 or with anti-CD3/B7-2–Ig. We saw only minor differences in Bcl-2 expression when CD28 and CD40L–costimulated T cells were assayed (Fig. 4 C). It is likely that the failure to enhance Bcl-xL in an environment where IL-2 was limited could result in significant apoptosis in these cultures.

CD28 fails to rescue CD4+ T cells from apoptosis after Anti-CD3/CD40L coligation. While T cell costimula-
tory molecules can work synergistically, fundamental differences exist among these molecules in their capacity to regulate T cell responses (45). To test whether CD28 ligation could reverse CD40L-induced apoptosis, we analyzed the kinetics of apoptosis among CD4+ T cells after the addition of beads containing anti-CD3/CD28 in cultures that were previously either unstimulated or stimulated with anti-CD3/CD40L (Fig. 5). Apoptosis was measured 24 h after restimulation of cultured cells. Interestingly, we found that even short culture (12 h) with anti-CD3/CD40L induced considerable apoptosis upon restimulation with anti-CD3/CD28. Conversely, relatively little apoptosis was seen in unstimulated cultures restimulated with anti-CD3/CD28. In all cases, anti-CD3/CD28 failed to decrease apoptosis in cells previously stimulated with anti-CD3/CD40L.

Our results point to an early and important role for CD40L in the modulation of T cell responses. Others have shown that CD40L expression is transient, and that the receptor is rapidly internalized after binding CD40 (46). Recently, it has been shown that CD40L is specifically regulated at the level of mRNA stability and that this regulation is not influenced by anti-CD3/CD28 costimulation (47, 48). Our in vivo findings show that the effects of hu5C8 are not solely mediated through the upregulation of CD80/CD86, as in a kidney allograft transplantation model, blocking anti-B7 mAbs did not yield similar results as those evident after treatment with hu5C8. Additionally, anti-CD80/CD86 mAbs act synergistically with hu5C8. This implies that hu5C8 imparts effects on transplanted grafts apart from B7 and therefore CD28-induced events (our unpublished data).

In this study, we have demonstrated that ligation of CD40L using the anti-CD40L mAb hu5C8 leads to specific CD28-independent short-term CD4+ T cell activation. However, anti-CD3/CD40L-mediated activation is aborted due to the enhanced production of immunomodulatory cytokines. Ultimately, this resulted in CD4+ T cell apoptosis consequent to the failure to induce IL-2, Bcl-2, or Bcl-xL expression. We believe that these in vitro results could point to a mechanism by which hu5C8 is working in vivo within our primate kidney allograft transplantation model. Others have recently highlighted the importance of apoptosis in the induction of long-term graft survivability.
Li et al. demonstrated that treatments that enhance the induction of apoptosis, such as CD28–B7 and CD40–CD40L blockade or costimulation blockade in conjunction with rapamycin treatment, promote peripheral allograft tolerance (50). Comparable to our results, anti-CD3/CD40L responses were blocked upon the addition of CSA. Wells et al. (49) provided additional support for a crucial role of apoptosis in transplantation tolerance. In studies that used Bcl-xL–transgenic and IL-2–deficient mice, they found that models that contained defective passive or active T cell apoptotic pathways were resistant to the induction of transplantation tolerance. Interestingly, the transplantation tolerance induced in the models presented in these studies and their previous work did not appear to depend on Fas-induced apoptosis (51). Similarly, in our work, a neutralizing mAb against Fas did not diminish the level of apoptosis that we measured after anti-CD3/CD40L ligation (data not shown). The mechanism by which costimulation blockade induces apoptosis of alloresponsive T cells is as yet unknown. It will be important to determine how current costimulatory regimens influence this process.

Our results imply that CD40L may directly signal downstream pathways in T cells. This is supported by data that indicate that the cytoplasmic domain of human and mouse CD40L is 82% identical (52) and contains structural elements that are functionally important (46). Aglycosylated hu5C8, which is unable to cross-link CD40L on the surface of T cells, does not prevent acute allograft rejection. Thus, anti-CD40L may exert its effect, at least in part, by direct T cell ligation (our unpublished data). CD40–CD40L interactions influence the gradual amplification of an immune response through the step-wise upregulation of adhesion and activation molecules. The ability of CD40L to regulate a response may depend on the availability of additional coreceptors and/or their cognate ligands as well as the activation status of the T cell. Teleologically, in the absence of additional costimulation, regulation of short-term responses through CD40L ligation could control damage from a prolonged immune response. An emerging question in the field of transplantation biology is how treatment regimens that act through the CD28–B7 and CD40L–CD40 pathways exert long-term effects after cessation of treatment. Defining the diverse roles of CD40–CD40L interactions and gaining a better understanding of the molecular pathways elicited after CD40L ligation will allow clinicians to identify additional therapeutic targets.

The authors are grateful for the administrative assistance provided by Amy Mosquera and Randall A. Carr and the technical assistance of Mark Shoemaker. We thank Dr. Bruce Levine and Julio Cotte for coordinating and assisting in blood draws at the National Naval Medical Center Blood Bank. Views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. government. Work was funded under Naval Medical Research Center Work Unit M 0095.003.1921.

References

1. Ochs H.D., D. Hollenbaugh, and A. Aruffo. 1994. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin. Immunol. 6:337–341.

2. Roy, M., T. Waldschmidt, A. Aruffo, J.A. Ledbetter, and R.J. Noelle. 1993. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J. Immunol. 151:2497–2510.

3. Castle, B.E., K. Kishimoto, C. Stearns, M.L. Brown, and M.R. Kehry. 1993. Regulation of expression of the ligand for CD40 on T helper lymphocytes. J. Immunol. 151:1777–1788.

4. Lederman, S., M.J. Yellin, A. Krichovsky, J. Belko, J.J. Lee, and L. Chess. 1992. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J. Exp. Med. 175:1091–1101.

5. Grewal, I.S., J. Xu, and R.A. Flavell. 1995. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378:617–620.

6. van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 378:620–623.

7. Kennedy, M.K., K.M. Mohler, K.D. Shanebeck, P.R. Baum, K.S. Picha, C.A. Otten-Evans, C.A. Janeway, Jr., and K.H. Gräbstein. 1994. Induction of B cell costimulatory function by recombinant murine CD40 ligand. Eur. J. Immunol. 24:114–123.

8. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263–1272.

9. Cayabyab, M., J.H. Phillips, and L.L. Lanier. 1994. CD40 preferentially costimulates activation of CD4+ T lymphocytes. J. Immunol. 152:1523–1531.

10. Peng, X., A. Kazarov, P.A. Wamermdam, M. de Boer, and J.L. Ceuppens. 1996. Accessory signaling by CD40 for T cell activation: induction of TH1 and TH2 cytokines and synergy with interleukin-12 for interferon-gamma production. Eur. J. Immunol. 26:1621–1627.

11. Brenner, B., U. Koppenhoefer, H. Grasme, J. Kun, F. Lang, and E. Gubmins. 1997. Evidence for a novel function of the CD40 ligand as a signalling molecule in T-lymphocytes. FEBS Lett. 417:301–306.

12. Koppenhoefer, U., B. Brenner, F. Lang, and E. Gubmins. 1997. The CD40-ligand stimulates T-lymphocytes via the neutralizing properties of CD40 and CD40L. J. Immunol. 158:444–448.

13. Zheng, X.X., T.G. Markey, W.W. Hancock, Y. Li, D.L. Greiner, X.C. Li, J.P. Mordes, M.H. Sayegh, A.A. Rossini, and T.B. Strom. 1999. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD45 monoclonal antibody treatment. J. Immunol. 162:4983–4990.

14. Sato, K., J. Sakurai, J. Ohata, T. Kohsaka, H. Hashimoto, K. Okumura, R. Abe, and M. Azuma. 1998. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells
lacking CD28. J. Immunol. 160:4225–4231.
15. Larsen, C.P., and T.C. Pearson. 1997. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr. Opin. Immunol. 9:641–647.
16. Parker, D.C., D.L. Greiner, N.E. Phillips, M.C. Appel, A.W. Steele, F.H. Durie, R.J. Nolle, J.P. Mordes, and A.A. Rossini. 1995. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. U.S.A. 92:9560–9564.
17. Pierson, R.N., A.C. Chang, M.G. Blum, K.S. Blair, M.A. Scott, J.B. Atkinson, B.J. Collins, J.P. Zhang, D.W. Thomas, L.C. Burkly, and G.G. Miller. 1999. Prolongation of primate skin and cardiac allografts after blocking CD40 and CD28 with established nephritis: preservation of kidney function. J. Immunol. 160:2158–2165.
18. Kalled, S.L., A.H. Cutler, S.K. Datta, and D.W. Thomas. 1998. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis preservation of kidney function. J. Immunol. 160:2158–2165.
19. Kim, A.D., D.M. Harlan, N.N. Armstrong, T.A. Davis, Y. Dong, G.S. Gray, X. Hong, D. Thomas, J.H. Fechner, Jr., and S.J. Knechtle. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. U.S.A. 94:8789–8794.
20. Kim, A.D., L.C. Burkly, D. Batty, R.E. Baumgartner, J.D. Berning, J.H. Fechner, Jr., R.L. Germond, R.L. Kampen, N.B. Patterson, S.J. Swanson, et al. 1999. Humanized anti-CD154 monoclonal antibody treatment prevents renal allograft rejection in non-human primates Nat. Med. 5:686–693.
21. Blair, P.J., L.H. Boise, S.P. Perfetto, B.L. Levine, G. McCray, K.F. Wagner, D.C. St. Louis, C.B. Thompson, J.N. Siegel, and C.H. June. 1997. Impaired induction of the apoptosis-protective protein Bcl-XI in asymptomatic HIV-infected individuals. J. Clin. Immunol. 17:234–246.
22. Wong, M.T., M.J. Dolan, E. Kozlow, R.D. Doyle, G.P. Mechler, D.S. Burke, R.N. Boswell, and M. Vaheny. 1996. Patterns of virus burden and T cell phenotype are established early and are correlated with the rate of disease progression in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 173:877–887.
23. Blotta, M.H., J.D. Marshall, R.H. DeKruyff, and D.T. Umetics. 1996. Cross-linking of the CD40 ligand on human CD4+ T lymphocytes generates a costimulatory signal that up-regulates IL-4 synthesis. J. Immunol. 156:3133–3140.
24. Shinde, S., Y. Wu, Y. Guo, Q. Niu, J. Xu, I.S. Grewal, R. Flavell, and Y. Liu. 1996. CD40 ligand is important for induction of, but not response to, costimulatory activity. J. Immunol. 157:2764–2768.
25. Gurunathan, S., K.R. Irvine, C.Y. Wu, J.I. Cohen, E. Thomas, C. Prusin, N.P. R. Edsio, and R.A. Seder. 1998. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J. Immunol. 161:4563–4571.
26. Chambers, C.A., and J.P. Allison. 1997. Co-stimulation in T cell responses. Curr. Opin. Immunol. 9:396–404.
27. June, C.H., J.A. Bluestone, L.M. Nadler, and C.B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today. 15:321–331.
28. Thompson, C.B., T. Lindsten, L.A. Ledbetter, S.L. Kunkel, H.A. Young, S.G. Emerson, J.M. Leiden, and C.H. June. 1989. CD28 activation pathway regulates the production of multiple T cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. U.S.A. 86:1333–1337.
29. Schreiber, S.L., and G.R. Crabtree. 1992. The mechanism of action of cyclosporin A and FK506. Immunol. Today. 13:136–142.
30. Shi, Y.F., B.M. Sahai, and D.R. Green. 1989. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 339:625–626.
31. June, C.H., J.A. Ledbetter, M.M. Gillespie, T. Lindsten, and C.B. Thompson. 1987. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant intercellular 2 gene expression. Mol. Cell. Biol. 7:4472–4481.
32. June, C.H., T. Lindsten, M.M. Gillespie, J.A. Ledbetter, and C.B. Thompson. 1989. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis preservation of kidney function. J. Immunol. 160:2158–2165.
33. Kirk, A.D., D.M. Harlan, N.N. Armstrong, T.A. Davis, Y. Dong, G.S. Gray, X. Hong, D. Thomas, J.H. Fechner, Jr., and S.J. Knechtle. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. U.S.A. 94:8789–8794.
34. Shinde, S., Y. Wu, Y. Guo, Q. Niu, J. Xu, I.S. Grewal, R. Flavell, and Y. Liu. 1996. CD40 ligand is important for induction of, but not response to, costimulatory activity. J. Immunol. 157:2764–2768.
by TNFα. Immunity. 11:423–432.

44. Boise, L.H., A.J. Minn, M.A. Accavitti, C.H. June, T. Lindsten, and C.B. Thompson. 1995. CD28 costimulation can promote T cell survival by inducing the expression of Bcl-XL. Immunity. 3:87–98.

45. Yashiro, Y., X.G. Tai, K. Toyo-oka, C.S. Park, R. Abe, T. Hamaoka, M. Kobayashi, S. Neben, and H. Fujiwara. 1998. A fundamental difference in the capacity to induce proliferation of naive T cells between CD28 and other co-stimulatory molecules. Eur. J. Immunol. 28:926–935.

46. Yellin, M.J., K. Sippel, G. Inghirami, L.R. Covey, J.J. Lee, J. Sinning, E.A. Clark, L. Chess, and S. Lederman. 1994. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function. J. Immunol. 152:598–608.

47. Rigby, W.F., M.G. Waugh, and B.J. Hamilton. 1999. Characterization of RNA binding proteins associated with CD40 ligand (CD154) mRNA turnover in human T lymphocytes. J. Immunol. 163:4199–4206.

48. Ford, G.S., B. Barnhart, S. Shone, and L.R. Covey. 1999. Regulation of CD154 (CD40 ligand) mRNA stability during T cell activation. J. Immunol. 162:4037–4044.

49. Wells, A.D., X.C. Li, Y. Li, M.C. Walsh, X.X. Zheng, Z. Wu, G. Nunez, A. Tang, M. Sayegh, W.W. Hancock, et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation. Nat. Med. 5:1303–1307.

50. Li, Y., X.C. Li, X.X. Zheng, A.D. Wells, L.A. Turka, and T.B. Strom. 1999. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft. Nat. Med. 5:1298–1302.

51. Li, X.C., Y. Li, I. Dodge, A.D. Wells, X.X. Zheng, L.A. Turka, and T.B. Strom. 1999. Induction of allograft tolerance in the absence of Fas-mediated apoptosis. J. Immunol. 163:2500–2507.

52. Farrah, T., and C.A. Smith. 1992. Emerging cytokine family. Nature 358:26.